Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Health Catalyst Fourth Quarter 2025 Earnings Call - CEO-Led Reset as DOS-to-Ignite Migration Puts $65M ARR at Risk
Health Catalyst closed 2025 with modest top-line progress and a management reset. Full-year revenue was $311.1 million, up 1% year over year, driven by a 7% rise in technology revenue to $208.3 millio...
- Leadership change and strategic reset: Ben Albert named CEO after Dan Burton’s departure, initiating a comprehensive review of product portfolio, cost structure, and go-to-market motion.
- Guidance limited: Company withheld full-year 2026 guidance, providing Q1 2026 revenue guidance of $68M to $70M and Adjusted EBITDA of $7M to $8M only.
- Revenue snapshot: Full-year 2025 revenue $311.1M, up 1% year over year; Q4 2025 revenue $74.7M versus $79.6M year-ago.
- +12 more takeaways
Hallador Energy Company Q4 2025 Earnings Call - ERAS slot secures pathway for gas expansion as accredited capacity prices surge
Hallador closed 2025 with improved profitability and a clear strategic shift toward becoming a vertically integrated independent power producer. Full year revenue rose 16% to $469.5 million, net incom...
- Hallador reported full-year 2025 revenue of $469.5 million, up 16% year-over-year, driven largely by electric sales growth.
- Net income improved materially to $41.9 million for 2025, and adjusted EBITDA increased about threefold to $56 million, showing operating leverage.
- Operating cash flow for 2025 rose 23% to $81.1 million, despite a weaker cash quarter-to-quarter driven by timing of prepaid contract receipts.
- +12 more takeaways
American Outdoor Brands Third Quarter Fiscal 2026 Earnings Call - Reiterated Guidance While Wrestling Tariff Hits, Aiming-Solutions Weakness, and a UST Impairment
American Outdoor Brands reported a mixed Q3: net sales of $56.6 million, down 3.3% year-over-year, but POS momentum and new-product traction underpin management confidence. The company held full-year ...
- Net sales were $56.6 million in Q3 FY26, down 3.3% year-over-year, but above company expectations.
- Point-of-sale grew 5% in the quarter, marking the third consecutive quarter of favorable POS results; management says adjusted sales would be high-single-digit growth when excluding two headwinds.
- Outdoor lifestyle generated 62% of net sales and grew 5.4% year-over-year, driven by BOG and MEAT! Your Maker.
- +12 more takeaways
Mission Produce Q1 FY2026 Earnings Call - Volume Growth Shields Margins as Calavo Deal Targets $25M in Synergies
Mission Produce navigated a sharp industry price reset in Q1 FY2026 by leaning into volume and per unit margin management, posting $278.6 million in revenue, down 17% year over year, while growing avo...
- Q1 revenue $278.6 million, down 17% year over year, driven by a ~30% decline in avocado pricing due to heavier Mexican supply.
- Avocado volumes up 14% in the quarter, underscoring the company’s volume-centric operating approach.
- Gross profit was flat at $31.6 million, while gross margin improved 190 basis points to 11.3% versus prior year.
- +12 more takeaways
SentinelOne Q4 FY2026 Earnings Call - Passed $1B, turned profitable, AI security drives record ARR
SentinelOne closed fiscal 2026 by crossing $1 billion in revenue, delivering full-year operating profitability and a record quarter for net new ARR. Q4 revenue was $271 million (up 20% YoY), total ARR...
- Scaled past $1 billion in revenue for FY2026, delivering 22% year-over-year revenue growth and achieving full-year operating profitability (operating margin 3.5% for FY2026).
- Q4 revenue was $271 million, up 20% YoY; total ARR grew 22% YoY and SentinelOne added a company-record $64 million of net new ARR in Q4.
- Management is pushing an upmarket strategy: customers with ARR >$1M grew to 153 (up 20% YoY), and customers with ARR >$100k reached 1,667 (up 18% YoY).
- +11 more takeaways
Ulta Beauty Q4 FY2025 Earnings Call - Investments Paying Off, Guiding to Profitable Growth and ~$1B Share Buybacks
Ulta closed fiscal 2025 with a clear message, execute then harvest. Sales rose roughly 10% to $12.4 billion, comps were +5.4% for the year and Q4 sales jumped 11.8% to $3.9 billion. Management says he...
- Fiscal 2025 net sales grew 9.7% to $12.4 billion; Q4 net sales rose 11.8% to $3.9 billion.
- Comparable sales were +5.4% for the year and +5.8% in the quarter; Q4 comps benefited from strong holiday execution and easier January compares.
- Full-year diluted EPS was $25.64, up 1.2% year over year; Q4 EPS was $8.01.
- +12 more takeaways
Corvus Pharmaceuticals Q4 2025 Earnings Call - Soquelitinib posts strong AD efficacy, durability and funds to push multiple mid-stage trials
Corvus closed 2025 with a heavier R&D spend focused on soquelitinib, an oral selective ITK inhibitor, and fresh financing that materially extends its runway. Cohort 4 phase 1 atopic dermatitis data sh...
- Company reported Q4 2025 net loss of $12.3 million, essentially flat with Q4 2024 ($12.1 million).
- R&D spend jumped to $9.9 million in Q4 and $33.7 million for full-year 2025, driven mainly by clinical and manufacturing costs for soquelitinib and higher personnel expense.
- Cash and marketable securities were $56.8 million as of December 31, 2025; an upsized January offering generated net proceeds of $189 million, giving pro forma cash of ~ $246 million and a runway into Q2 2028, per management.
- +12 more takeaways
KORU Medical Systems Q4 2025 Earnings Call - CEO Exit and Succession as Company Guides to 2026 Profitability
KORU closed 2025 with clear momentum, reporting Q4 revenue of $10.9 million and full year revenue of $41.1 million, a 22% increase year over year. Management is pitching 2026 as the year to convert th...
- CEO transition announced, Linda Tharby to retire effective June 30, 2026, Adam Kalbermatten promoted to President March 15 and to become CEO July 1, providing planned leadership continuity.
- Q4 revenue $10.9 million, marking a third consecutive quarter of >20% revenue growth; full year 2025 revenue $41.1 million, up 22% year over year.
- Company initiated 2026 guidance of $47.5 million to $50 million in revenue, implying 15% to 22% growth, with targeted gross margins of 61% to 63%, positive adjusted EBITDA, and full year positive cash flow.
- +11 more takeaways
Mineralys Therapeutics Q4 2025 Earnings Call - FDA Accepts NDA for Lorundrostat, PDUFA Dec 22, 2026
Mineralys announced FDA acceptance of its NDA for lorundrostat with a PDUFA action date of December 22, 2026, moving the aldosterone synthase inhibitor from late-stage development toward a potential U...
- FDA accepted Mineralys Therapeutics NDA for lorundrostat, FDA set PDUFA target action date of December 22, 2026.
- NDA is supported by five clinical trials, notably pivotal Launch-HTN and Advance-HTN, plus Explore-CKD and the Transform-HTN open label extension.
- Lorundrostat delivered consistent, clinically meaningful blood pressure reductions and 24-hour control across trials, with a favorable safety profile.
- +15 more takeaways
GrabAGun Digital Holdings Q4 2025 Earnings Call - PEW Logistics launch signals shift from retailer to software-style platform
GrabAGun closed Q4 with clear top-line momentum and a strategic pivot. Q4 revenue was $29.6 million, up 14.1% year-over-year, driven by a 19.1% increase in firearm sales and 11.5% volume growth, outpe...
- Q4 net revenue of $29.6 million, up 14.1% year-over-year, was the company’s strongest quarter in 2025.
- Firearm sales were $25.7 million in Q4, up 19.1%, driven by 11.5% volume growth and favorable mix/pricing dynamics.
- Company outgrew the broader category while adjusted NICS background checks declined 4.1% in the same period, signaling market share gains rather than pure market tailwinds.
- +17 more takeaways